

- Ischemic stroke, clinical features of (*Cont.*):
 with common carotid artery occlusion, 2574
 inferior pontine syndrome, 2577f
 with internal carotid artery occlusion, 2574, 2574f, 2575f
 medullary syndrome, 2576f
 midbrain syndrome, 2580f
 with middle cerebral artery occlusion, 2572–2573, 2573f
 midpontine syndrome, 2578f
 with posterior cerebral artery occlusion, 2574–2575, 2574f, 2575f
 with posterior inferior cerebellar artery occlusion, 2576–2577
 superior pontine syndrome, 2579f
 with vertebral artery occlusion, 2575–2576, 2575f
- etiology of, 2563, 2565t
 artery-to-artery, 2564–2565
 CADASIL, 2568
 cardioembolic, 2563–2564
 CNS vasculitis, 2568
 CNS vasculopathy, 2568, 2568f
 drug-related, 2568
 Fabry's disease, 432e-1, 2568
 fibromuscular dysplasia, 2567
 giant cell arteritis, 2567
 hypercoagulable disorders, 2565–2566
 leukoaraiosis, 2568
 moyamoya disease, 2568
 necrotizing arteritis, 2567–2568
 sickle cell anemia, 636, 2567
 small-vessel, 2564, 2567f
 venous sinus thrombosis, 2566–2567
- imaging in, 2580–2581, 2581f, 2582f
 pathophysiology of, 2560–2561, 2561f, 2563, 2564f
- prevention of, 2569
 anticoagulation therapy for, 2570–2571
 antiplatelet agents for, 291e-9, 747, 2566t, 2569–2570
 risk factor management in, 2569
- treatment of, 2561
 algorithm for, 2560f
 anticoagulants, 2563
 antithrombotic agents, 2563
 endovascular techniques, 2562–2563
 intravenous thrombolysis, 2561–2562, 2562t
 medical support, 2561
 neuroprotection, 2563
 rehabilitation, 2563
 stroke centers in, 2563
- Ischial bursitis, 2247
 Isfahan virus, 1310t
 Ishihara color plates, 197
 ISI (International Sensitivity Index), 405, 755, 1998
 Islet-1, 265e-11
 Islet amyloid polypeptide (IAPP), 2402
 Islet cell(s)
 adenoma of, 536
 pancreatic, 2403–2404
 regeneration of, 90e-3
 tumors of. *See* Pancreatic neuroendocrine tumors (pNETs)
- Islet cell autoantibodies, 2404
 Isoagglutinins, 138e-1
 Isobutyl-CoA dehydrogenase deficiency, 434e-3t
 Isocarboxazid, 2710t
 Isocyanate exposure, 1692t
 Isoflavones, 96e-6
 Isoforms, 427
 Isolated stem cells, 453
 Isolation aphasia, 177t, 178
 Isolation techniques, 916
 Isoleucine metabolism disorders, 434e-3t
 Isometheptene, 2592, 2592t
 Isomorphic (Koebner's) phenomenon, 347
 Isoniazid (INH)
 action of, 205e-2–3
 adverse effects of, 205e-3
 acid-base disorders, 318
 cutaneous, 353, 360
 fever, 138
 hepatotoxicity, 40, 205e-3, 1121, 2023, 2025t, 2028
 lupus syndrome, 2218t
 neuropathy, 205e-3, 2687t, 2689
 optic neuropathy, 203
 pellagra, 96e-4
 pure red cell aplasia, 668t
 pyridoxine for prevention of, 96e-4, 205e-3, 1116
 seizure, 2547t
 dosage of, 205e-3
 drug interactions of, 205e-3, 246e-3t
 genetic variations in response to, 39t, 40
 metabolism of, 34t
 for nontuberculous mycobacterial infections, 1131–1132
 overdose/poisoning with, 473e-5, 473e-12t
 pharmacology of, 205e-3
 resistance to, 205e-3, 1118
 for TB
 active infection, 205e-2–3, 205e-2t, 1115t, 1116–1117, 1116t
 latent infection, 205e-1t, 205e-2t, 1121
 prophylaxis in HIV infection, 1251t
 for tuberculous meningitis, 898
- Isoprinosine, 900
 Isopropyl alcohol poisoning, 319
 8-Isoprostane, 1674
 Isoproterenol, 1469, 1473, 1474
 Isosexual precocity, 2361
 Isosorbide, 1512t, 1588t, 1608, 1763
Isospora belli/isosporiasis. *See* *Cystoisospora belli* cystoisosporiasis
- Isotretinoin
 for acne vulgaris, 352
 adverse effects of, 352, 354, 380, 380f, 2218t
 for oral leukoplakia, 477
 for pityriasis rubra pilaris, 354t
- Isotypes, of immunoglobulins, 710
 Isovaleric acidemia, 434e-3t
 Isradipine, 1589, 1589t, 1649
 Israeli spotted fever, 1157
 ITAMs (Immunoreceptor tyrosine-based activation motifs), 372e-19, 2115
- Itaqui virus, 1309t
ITPA gene, 39, 39t
- Itraconazole
 adverse effects of, 246e-3t, 1331
 for *Aspergillus* infections, 1348, 1349t, 1681
 for *Aspergillus* prophylaxis, 1349
 for *Blastomyces* infections, 1338, 1339t
 for *Candida* infections, 233, 1345
 for *Coccidioides* infections, 1336
 contraindications to, 350
 for dermatophyte infections, 1358, 1358t
 drug interactions of, 34t, 42t, 246e-3t, 328
 for *Histoplasma* infections, 899, 1334, 1334t
 indications for, 1331
 for *Malassezia* infections, 1357
 for onychomycosis, 350t, 1358, 1358t
 for paracoccidioidomycosis, 1354, 1354t
 for penicilliosis, 1354t
 in pregnancy and lactation, 246e-3t
 prophylactic use, in HIV infection, 1252t
 resistance to, 1348
 for *Sporothrix* infections, 1354, 1354t
 susceptibility testing for, 150e-8
 for thrush, 233
 for tinea versicolor, 350
- IUDs. *See* Intrauterine devices (IUDs)
- Ivabradine, 1477, 1512
 Ivacaftor, 1699
- Ivermectin
 action of, 246e-9
 adverse effects of, 246e-4t, 246e-9, 1420, 1421, 1422
 for ascariasis, 1413–1414
 for cutaneous larva migrans, 1411t
 for gnathostomiasis, 1411t
 indications for, 246e-9
 for loiasis, 1422
 for lymphatic filariasis, 1419
 for onchocerciasis, 1421
 pharmacology of, 246e-9
 in pregnancy and lactation, 246e-4t
 resistance to, 246e-9
 for scabies, 2745
 for strongyloidiasis, 1416
 for trichuriasis, 1416
- IVF (in vitro fertilization), 444, 2360, 2389
 IVIg. *See* Intravenous immunoglobulin (IVIg)
 "Ivory vertebra," 426e-2
 Ixabepilone, 103e-12t, 103e-15
Ixodes spp. ticks. *See also* Tick(s)
 in arborviral encephalitis, 1316
 in *Babesia* infections, 1384. *See also* *Babesia* spp. infections
 characteristics and life cycle of, 1149, 2745, 2746f
 climate change and habitat of, 151e-6, 151e-6f
 in human granulocytotropic anaplasmosis, 1160
 in Lyme borreliosis, 1149, 2745. *See also* Lyme borreliosis (Lyme disease)
 in relapsing fever transmission, 1146. *See also* Relapsing fever
 removal of, 2745
- Ixodid (hard) tick, 2745
 Izumi fever, 1077
- ## J
- Jackhammer esophagus, 1906f
 Jacksonian epilepsy, 1427
 "Jacksonian march," 2542
 Jacobsen syndrome, 375e-2
 Jaffe reaction, 480e-2
 JAK (Janus family of protein tyrosine kinases), 372e-16, 401e-3, 2143
- JAK2 gene mutations
 in IBD, 1949, 1950t
 in MDS/MPN, 135e-6
 in polycythemia vera, 400, 672–673, 674, 675
- JAK2 inhibitors, 102e-3, 674
 JAK3 deficiency, 372e-16
 JAK3 gene mutations, 135e-3
 Jamaica bush tea, 283
 Jamestown Canyon virus, 1309t, 1315
 Janeway lesions, 784, 818f, 1443
 Jansen's chondrodystrophy, 2458
 Jansen's disease, 2475, 2476f
 Japanese encephalitis virus, 1306t, 1315
 Japanese encephalitis virus vaccine, 795, 795t
 Japanese spotted fever, 1157
 Jargon aphasia, 177
 Jarisch-Herxheimer reaction
 in leptospirosis, 1145
 in Lyme disease, 1153
 in Q fever, 1162
 in relapsing fever, 1147, 1148
 in syphilis, 1140, 1259
 in Whipple's disease, 1094
- Jaundice, 279
 in acute viral hepatitis, 2015, 2016
 approach to the patient, 280–281, 281f
 with ascites, 283
 breast milk, 2001
 in cardiovascular disease, 1442
 in cholelithiasis, 2084
 in cholestatic disorders, 283–285, 284t, 2080
 in chronic hepatitis, 2033
 in clinical drug trials, 2025
 differential diagnosis of, 279–280, 1877, 1877t
 drug-induced, 283, 283t, 284
 global considerations in, 285
 in hemolytic anemia, 649
 in hepatocellular conditions, 283, 283t
 history in, 282
 laboratory evaluation of, 280, 283
 in liver disease, 1991
 neonatal, 653, 654, 2001
 in pancreatic cancer, 554–555
 pathophysiology of, 280
 physical examination in, 282–283
 in sepsis/septic shock, 1755
- Jaw, osteonecrosis of, 242, 623, 2481, 2501